Greeting

Since its establishment in 1956, Korea Vaccine has contributed to the domestic and foreign health care industry by introducing various vaccines such as influenza, hepatitis B, folio, DTaP, measles, and various medical consumables such as disposable syringes, IV Set, and IV Catheters through continuous investment over the past 70 years.

Currently, through GMP certification based on WHO and PIC/S, consignment production and test services are provided for various biopharmaceuticals in addition to biopharmaceuticals such as seasonal influenza vaccines.
Based on the new BIOPLANT completed in 2023, our Korean vaccine is developing and producing new vaccines and expanding its capacity as a CDMO by introducing a cell culture-based undiluted solution production system beyond the existing fill & finish area. To this end, we have established an R&D center and are cooperating with a number of companies.

In the medical device business, in order to secure a more diverse portfolio, we are investing in our own production bases overseas and through this, we want to expand our entry into overseas markets.

In the future, Korea Vaccine aims to become a global comprehensive medical service company responsible for human health beyond the health of the people by expanding and strengthening its business as a vaccine company that covers everything from undiluted to final medicines and as a medical device maker competing in the global market with leading medical device companies around the world.

Thank you.

CEO HASEONGBAE

Established in 1956, KOREAVACCINE has significantly contributed over the past 70 years to both the domestic and international healthcare fields through continuous investments, which include the introduction of Korea’s biggest PFS filling facility and automation system, the manufacturing of various vaccines for influenza, hepatitis B, polio, DTaP, measles, and other diseases, along with biopharmaceuticals like antitoxins and numerous medical products such as disposable syringes, IV sets, and IV catheters.

Currently, we provide consignment production and testing services for a range of biopharmaceuticals such as seasonal influenza vaccines, in accordance with GMP certification based on WHO and PIC/S standards.

With the establishment of the new Bioplant in 2023, KOREAVACCINE is strengthening its capabilities as a CDMO and is engaged in the development and manufacturing of new vaccines by implementing a cell culture-based API(Active Pharmaceutical Ingredient) production system that extends beyond the existing fill and finish area. To achieve this, we have established an R&D center and are collaborating with multiple companies.

In order to achieve a more varied portfolio in the medical device industry, we are investing in our own manufacturing facilities abroad, and through this effort, we intend to grow our presence in international market.

In the future, KOREAVACCINE will enhance and reinforce its operations as a specialized vaccine company encompassing all aspects from DS(Drug Substance) to DP(Drug Products), and as a medical device manufacturer competing in the international market alongside leading medical device companies worldwide. KOREAVACCINE will progress as a global comprehensive medical service provider responsible for the health of humanity beyond the wellness of individuals.

Thank you.

CEO HA SUNG BAE